Nasdaq

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven Pharmaceutical BHVN incurred loss of $4.27 per share in first-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $2.92 as well as the year-ago loss of $3.07. Adjusted loss for ...
Main Line

Following the Recent Label Expansion, Biohaven’s Nurtec ODT Has Come Out Strong in the Migraine Prevention Market, According to Spherix Global Insights

EXTON, Pa., Sept. 9, 2021 /PRNewswire/ — In May 2021, the FDA approved the label expansion of Biohaven’s Nurtec ODT for the preventive treatment of episodic migraine, making the gepant the first and ...
Nasdaq

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

- Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020 NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- ...
Main Line

Biohaven’s Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly’s Emgality, According to Spherix ...

EXTON, Pa., Sept. 23, 2021 /PRNewswire/ — Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli Lilly announced initiation of a ...
Business Insider

Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program

MOORESVILLE, N.C., May 14, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT ...
Heavy.com

Cody Ware Reaches Extension With Primary Partner

The purple No. 51 Ford Mustang will return for the 2022 NASCAR Cup Series season. Biohaven Pharmaceuticals, the company behind Nurtec ODT, has agreed to an extension with Rick Ware Racing and Cody ...